Dashboard
Manage Tickers

ZYME Zymeworks Inc.

Nasdaq zymeworks.com


$ 16.45 $ -1.44 (-8.04 %)    

Friday, 07-Nov-2025 15:59:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 16.46
$ 17.01
$ 12.00 x 50
$ 18.70 x 600
$ 16.00 - $ 17.22
$ 9.03 - $ 19.98
1,481,658
na
1.04B
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-05-2025 01-01-1970 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 03-06-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wells-fargo-maintains-equal-weight-on-zymeworks-raises-price-target-to-17
Wells Fargo Maintains Equal-Weight on Zyme...
11/07/2025 18:54:52

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Equal-Weight and raises the price target fro...

zymeworks-q3-eps-026-beats-035-estimate-sales-27614m-miss-29460m-estimate
Zymeworks Q3 EPS $(0.26) Beats $(0.35) Est...
11/06/2025 21:19:34

Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.35) by ...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

5-analysts-have-this-to-say-about-zymeworks
5 Analysts Have This To Say About Zymeworks
10/24/2025 12:01:42

zymeworks-announces-preliminary-results-from-phase-1-study-evaluating-zw191-adc-targeting-folate-receptor-alpha-at-aacr-nci-eortc-conference
Zymeworks Announces Preliminary Results Fr...
10/23/2025 16:32:55

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced...

jp-morgan-maintains-overweight-on-zymeworks-raises-price-target-to-23
JP Morgan Maintains Overweight on Zymework...
10/16/2025 11:48:53

JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $20 to $23.

broadcom-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-tuesday
Broadcom To Rally More Than 12%? Here Are ...
10/14/2025 12:25:08

this-rpm-international-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday
This RPM International Analyst Turns Bulli...
10/14/2025 12:00:55

hc-wainwright--co-upgrades-zymeworks-to-buy-raises-price-target-to-26
HC Wainwright & Co. Upgrades Zymeworks to ...
10/14/2025 11:15:14

HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks (NASDAQ:ZYME) from Neutral to Buy and raises the price targe...

zymeworks-to-present-preliminary-results-from-phase-1-study-evaluating-zw191-adc-targeting-folate-receptor--at-aacr-nci-eortc-conference-2025
Zymeworks To Present Preliminary Results F...
10/13/2025 20:02:36

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with ...

b-riley-securities-initiates-coverage-on-zymeworks-with-buy-rating-announces-price-target-of-30
B. Riley Securities Initiates Coverage On ...
10/10/2025 13:28:05

B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks (NASDAQ:ZYME) with a Buy rating and announces Pri...

zymeworks-pulls-plug-on-early-stage-cancer-potential-as-therapy-unlikely-to-provide-benefit
Zymeworks Pulls Plug On Early-Stage Cancer...
09/02/2025 16:30:13

Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, includin...

zymeworks-discontinues-clinical-development-of-mesothelin-directed-t-cell-engager-zw171-following-phase-1-dose-escalation-review
Zymeworks Discontinues Clinical Developmen...
09/02/2025 10:06:15

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
08/22/2025 21:07:35

citigroup-maintains-buy-on-zymeworks-raises-price-target-to-22
Citigroup Maintains Buy on Zymeworks, Rais...
08/11/2025 13:00:44

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $19 to $22.

zymeworks-q2-eps-003-beats-049-estimate-sales-4873m-beat-1938m-estimate
Zymeworks Q2 EPS $0.03 Beats $(0.49) Estim...
08/07/2025 20:10:44

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

the-fda-has-cleared-zymeworks-investigational-new-drug-application-for-zw251-a-novel-glypican-3-targeted-adc-incorporating-the-companys-topoisomerase-1-inhibitor-payload-zd06519-for-hepatocellular-carcinoma-the-company-plans-to-start-phase-1-studies-for-zw251-in-2025
The FDA Has Cleared Zymeworks' Investigati...
07/28/2025 10:09:27

hc-wainwright--co-reiterates-neutral-on-zymeworks-maintains-13-price-target
HC Wainwright & Co. Reiterates Neutral on ...
07/03/2025 10:57:13

HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $13 price target.

zymeworks-reveals-nmpa-approval-of-zanidatamab-in-china-for-adults-with-previously-treated-unresectable-or-metastatic-her2-high-expression-ihc3-biliary-tract-cancer-says-20m-milestone-payment-to-be-received-from-beone-medicines
Zymeworks Reveals NMPA Approval Of Zanidat...
05/30/2025 10:03:01

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION